Skip to main content
Careers
Contact us
Company
About Us
Management
Board of Directors
Advisory Board
Therapeutic Focus
Neurological Disorders
Chronic Pain
Hair Loss Disorders
Science and Technology
Exicure's Approach
References and Papers
Pipeline
Pipeline
Collaboration Programs
Partnering and Licensing
Investors
Investors
News
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Form 8937
Financials
Interactive Financials
Financial Summary
SEC Filings
Annual Reports
Governance
Executive Management
Board of Directors
Governance Documents
Committee Composition
Resources
Contact IR
FAQs
Email Alerts
News
Company
About Us
Management
Board of Directors
Advisory Board
Scientific Team
Therapeutic Focus
Genetic Disorders
Oncology
Science and Technology
Pipeline
Pipeline
AST-008
XCUR-FXN
Collaboration Programs
Compassionate Use Policy
Partnering and Licensing
Investors
Investors
News
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Form 8937
Financials
Interactive Financials
Financial Summary
SEC Filings
Annual Reports
Governance
Executive Management
Board of Directors
Governance Documents
Committee Composition
Resources
Contact IR
FAQs
Email Alerts
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
2015
2014
09/26/2022
Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives
09/01/2022
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
08/15/2022
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress
07/20/2022
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
06/29/2022
Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split
05/27/2022
Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders
05/17/2022
Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
05/16/2022
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
05/10/2022
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium
05/09/2022
Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference
03/25/2022
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress
02/04/2022
Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors